Harvard Apparatus Regenerative Technology Inc (HRGN) USD0.01
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
- Add to watchlist
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
Business summary
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.
Contact details
Important dates
General stock information
- Short code:
- HRGN
- ISIN:
- US09074M2026
- Market cap:
- $31.97 million
- Shares in issue:
- 14.53 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.